931P - Clinical outcome in patients with primary advanced or metastatic endometrial carcinoma treated with standard chemotherapy regimen according differe...

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Endometrial Cancer
Presenter Marijana Milovic
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors M.M. Milovic1, D. Gavrilovic2, L. Stamatovic1
  • 1Medical Oncology, Institute of Oncology and Radiology of Serbia, 11000 - Belgrade/YU
  • 2Data Center, Institute for oncology and radiology of Serbia, 11000 - Belgrade/YU



The aim of this study was to investigate difference in clinical outcome in patients with primary advanced or metastaitic endometrial cancer treated with standard chemotherapy doxorubicin-cisplatin (DOX-CDDP), regarding and focusing on histological subtype.


Eligible patients had histologically-proven advanced and/or metastatic endometrial adenocarcinoma and were chemotherapy-naive. Treatment consisted of CDDP 50 mg/m2 added to DOX 60 mg/m2, every 3 weeks. Kaplan Maier method and Log rank test were used to assess survival prognostic factors. Median age was 64 years (range 34-77). Patients were divided into 2 groups according histopathologic type: Type 1 EC- endometrioid and Type 2 EC- serous/clear cell/ undifferentiated type. Between 2007 and 2012, we analysed 18 patients (60%) with Type 2 EC (6 papillary serous, 11 clear cell, 1 undifferentiated) and 12 patients (40%) with Type 1 EC.


FIGO stages were as follows: FIGO III = 18 (60%), FIGO IV = 12 (40%). Response for Type 1 EC was as follows: 12 (100%) patients had partial and complete remission (responders). Response for Type 2 was as follows: 7 patients (39%) had stable disease(SD) and 11 patients (61%) had partial and complete remission (responders).The combination DOX–CDDP provided a significantly greater therapeutic response in Type 1 EC compared to Type 2 EC ( Fischer Exact test; p =0.024). At time of analysis 76% of patients were still alive after median follow up of 21 months (9-58). Median progression free survival (PFS) for Type 1 EC was 18 months (range 8-56). Median progression free survival (PFS) for Type 2 EC was 11 months (5-26), so there was demonstrated significant difference between Type 1 and Type 2 EC according PFS (Log-Rank test; p = 0.0014). It was also shown trend in significance between Type 1 and 2 EC according OS (Log-Rank test; p = 0.062).


Type 2 endometrial cancer is rare and differs from Type 1 especially for the high frequency of distant metastasis. Our results indicate that there is demonstrated worse response and outcomes to standard chemotherapy in Type 2 EC compared to Type 1 EC, so multicentric studies are needed to better define appropriate management for these kind of malignancies.


All authors have declared no conflicts of interest.